In this episode of On The Line, BioCanRx President and CEO Stephanie Michaud joins Matt Gurney for a conversation about one of the biggest problems facing Canadian health care: Canada produces world-class medical research, but too often struggles to turn those discoveries into treatments that actually reach Canadian patients.

Stephanie explains why it can take so long for the newest and most promising therapies to make their way into the Canadian healthcare system — and why so much science developed by Canadian researchers ultimately ends up being commercialized in the United States. Canada has extraordinary researchers and institutions. So why do we keep losing the economic and medical benefits of their work?

This episode is brought to you by the Forest Products Association of Canada. Budget season in Ottawa is filled with asks for new programs, new tax measures and new investment. But for Canada’s forest products sector, the biggest opportunity for growth doesn’t require new spending — it requires smarter rules. Regulatory inefficiencies are costing the average Canadian mill an estimated one million dollars a year each. That’s money that could be reinvested in workers, communities, and modernization instead. The Forest Sector Transformation Task Force gave Ottawa a clear playbook. As the federal budget takes shape, the fastest way to unlock private investment is to remove the made-in-Canada barriers standing in the way. Learn more at FPAC.ca.

Matt and Stephanie also discuss what it would take for Canada to become more independent of the United States in biotechnology and healthcare. If Canadians really want to get their elbows up, this is one area where the country already has many of the ingredients it needs. They look at opportunities to work with international partners, build domestic capacity and create a system capable of taking Canadian discoveries from the laboratory all the way to Canadian patients.

And, unusually for On The Line, there’s some optimism. Stephanie believes Canada has a genuine opportunity to build on its existing strengths and become a global leader in biotechnology — creating economic opportunities while also helping Canadians survive terrible diseases and live longer, healthier lives.

This episode is also brought to you by Cameco. Building Canada’s energy future means creating jobs for Canadian workers. That’s why the AP1000 reactor is the right choice for Canada: it is already operating and ready to deliver the power we need. Choosing the AP1000 means a reactor built by Canadians, creating skilled jobs in construction, fabrication and the trades while keeping more investment and economic benefits here at home. If we are serious about creating Canadian jobs and strengthening our economy, the choice is clear. To learn more, visit ap1000.cameco.com.

Disclosures x 2: BioCanRx has been and remains a sponsor of The Line. This was an interview we wanted to do because of what Matt Gurney learned while his wife battled a devastating cancer diagnosis; an employee at BioCanRx is an old friend of Matt's and offered his help soon after the diagnosis, which is how The Line and BioCanRx began speaking in the first place. For the record: BioCanRx did not seek or receive any editorial control over this interview, was not provided questions in advance, nor asked for them, and requested no changes to the finished product. For further transparency, the only edits to this podcast were to cover your intrepid host choking while sipping water, like the seasoned broadcast professional he is, and a doorbell ringing. Exciting times!

Check out our main page at ReadTheLine.ca, and as always like and subscribe.

#OnTheLine #BioCanRx #StephanieMichaud #CanadianHealthcare #Biotechnology #CanadianInnovation #HealthInnovation #CancerResearch #LifeSciences #MedicalResearch #CanadaUS #MattGurney

In the latest episode of The Line Podcast, Matt Gurney returns from a leave to care for his wife and wonders if he’s missed anything over the last two weeks. Turns out he has. It’s his first chance to sit down with Jen Gerson and talk about the Alberta referendum, and Jen — finally having gotten some sleep — offers her concluding thoughts on … all that. Matt gives his reactions and asks Jen a fairly basic question: what, exactly, was the point of the whole exercise? They agree that Danielle Smith doesn’t come out of it looking particularly good. They also agree she might just skate anyway, especially since the separatists lost so badly that a lot of them might just move on to the next grift.

This episode is brought to you by BioCanRx. We’ve been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re addressing common questions, like: is Canada behind on immunotherapy?

Canadian researchers continue to be global leaders at discovery research. Where Canada lags behind is in bringing these discoveries from the lab to the patient. While many immunotherapies come to Canada for clinical trial or market authorization, few are based on Canadian research or developed in Canada, meaning we access them when their international sponsors choose, at whatever prices they want to charge –– provided Health Canada approves and the provinces decide to pay.

Developing more Canadian discoveries into approved therapies in Canada would help reduce Canada’s dependence on other countries, enable our health systems to learn what it takes to deliver these novel therapies while collecting data to assess their value via early stage clinical trials, and provide patients with much-needed access to advanced therapies. A win-win-win scenario.

BioCanRx continues to work with researchers and policymakers to deliver on this mission. Thanks to them for continuing to partner with The Line to share this information and visit BioCanRx.com to learn more.

Next, your hosts turn to the catastrophe at CFB Wainwright, where some of the worst instincts of Canadian governance were on full display. The safety of the troops and care for the families of the fallen obviously come first. But the disaster also became a textbook example of how Canadian institutions respond to emergencies by smothering transparency. Matt and Jen go through what was known, what was revealed and, yes, read aloud what may be the worst official communication ever produced by a Canadian government comms person. Matt also responds to criticism that the military probably didn’t yet know the answers to the questions The Line wanted answered. There’s just one problem with that defence: someone leaked The Line the memo. They knew. So ....

Finally, Matt offers a personal update on the family medical emergency that took him away from the podcast. He’s still figuring out how much he can and should say publicly, but he has some broader thoughts about Canada’s health-care system. It turns out all the clichés are true: it can be astonishingly good and absolutely awful at the same time. Matt also has some very sharp and specific criticisms of one group of hospital professionals. He thinks the problems there are serious enough that they could end up collapsing the system, literally. Canadians will die because of this; Canadians are already dying of it, and Matt got to watch one of those deaths with his own eyes.

The harder question is what anyone can do about it.

All that, and more, in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. Like and subscribe.

#TheLinePodcast

#AlbertaReferendum
#DanielleSmith
#CFBWainwright
#CanadianForces
#CanadianMilitary
#CanadianPolitics
#GovernmentTransparency
#CanadianHealthcare
#HealthcareCrisis

In this episode of On The Line, host Jen Gerson speaks with Patrick Lennox, author of On Treason, a new book examining the moral and political consequences of betraying one's own country. Their conversation focuses on Alberta's separatist movement, its reported efforts to secure American recognition for a future independent state, and why Lennox believes the movement represents something more troubling than ordinary regional grievance politics.

This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re addressing common questions, like: is Canada behind on immunotherapy?

Canadian researchers continue to be global leaders at discovery research. Where Canada lags behind is in bringing these discoveries from the lab to the patient. While many immunotherapies come to Canada for clinical trial or market authorization, few are based on Canadian research or developed in Canada, meaning we access them when their international sponsors choose, at whatever prices they want to charge –– provided Health Canada approves and the provinces decide to pay.

Developing more Canadian discoveries into approved therapies in Canada would help reduce Canada’s dependence on other countries, enable our health systems to learn what it takes to deliver these novel therapies while collecting data to assess their value via early stage clinical trials, and provide patients with much-needed access to advanced therapies. A win-win-win scenario.

BioCanRx continues to work with researchers and policymakers to deliver on this mission. Thanks to them for continuing to partner with The Line to share this information and visit BioCanRx.com to learn more.

Lennox traces the political developments that brought Alberta to the brink of a separatist referendum, including Bill 54 and changes to the province's citizens' initiative rules. They discuss lower signature thresholds, corporate financing, and the role these changes have played in opening a path to a referendum. Lennox argues that the process reflects deliberate political engineering rather than a spontaneous expression of popular discontent.

This episode is also brought to you by the Forest Products Association of Canada. Budget season in Ottawa is filled with asks for new programs, new tax measures and new investment. But for Canada’s forest products sector, the biggest opportunity for growth doesn’t require new spending — it requires smarter rules. Regulatory inefficiencies are costing the average Canadian mill an estimated one million dollars a year each. That’s money that could be reinvested in workers, communities, and modernization instead. The Forest Sector Transformation Task Force gave Ottawa a clear playbook. As the federal budget takes shape, the fastest way to unlock private investment is to remove the made-in-Canada barriers standing in the way. Learn more at FPAC.ca.

Jen and Lennox also examine the role of unelected separatist organizers, questions of democratic legitimacy, and the possibility of foreign interference. At what point does advocating for independence cross the line into something more serious? And what happens when a domestic political movement seeks support from a foreign government whose interests may be fundamentally opposed to Canada's?

This episode is also brought to you by Cameco. Building Canada’s energy future means creating jobs for Canadian workers. That’s why the AP1000 reactor is the right choice for Canada: it is already operating and ready to deliver the power we need. Choosing the AP1000 means a reactor built by Canadians, creating skilled jobs in construction, fabrication and the trades while keeping more investment and economic benefits here at home. If we are serious about creating Canadian jobs and strengthening our economy, the choice is clear. To learn more, visit ap1000.cameco.com.

It's a conversation about Alberta separatism, sovereignty, democratic accountability, and why Lennox believes Canadians need to take the threat of treason seriously in an increasingly unstable geopolitical environment.

Check out our main page at ReadTheLine.ca, and as always, like and subscribe.

#OnTheLine #PatrickLennox #OnTreason #AlbertaSeparatism #AlbertaPolitics #CanadaPolitics #Bill54 #ForeignInterference #CanadianSovereignty #Federalism #JenGerson